Liquid biopsy in bone sarcomas and identification of new biomarkers
暂无分享,去创建一个
[1] Raghu Kalluri,et al. The biology, function, and biomedical applications of exosomes , 2020, Science.
[2] M. Mikuła,et al. Signatures of circulating microRNA in four sarcoma subtypes , 2020, Journal of Cancer.
[3] E. Pérez-Hernández,et al. Metabolic profiling of serum in patients with cartilage tumours using 1H‐NMR spectroscopy: A pilot study , 2020, Magnetic resonance in chemistry : MRC.
[4] M. Heymann,et al. Circulating Tumor Cells as a Tool for Assessing Tumor Heterogeneity , 2019, Theranostics.
[5] S. Lee,et al. Technologies for circulating tumor cell separation from whole blood , 2019, Journal of Hematology & Oncology.
[6] S. M. Taghdisi,et al. Exosomes, new biomarkers in early cancer detection. , 2019, Analytical biochemistry.
[7] Zhen Wang,et al. Prognostic and clinicopathological significance of circulating tumor cells in osteosarcoma , 2019, Journal of bone oncology.
[8] P. Cartron,et al. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer , 2019, Biochemical pharmacology.
[9] G. Ha,et al. Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group , 2019, British Journal of Cancer.
[10] M. Heymann,et al. Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? , 2019, Drug discovery today.
[11] Y. Zhang,et al. Exosomes: biogenesis, biologic function and clinical potential , 2019, Cell & Bioscience.
[12] C. Deng,et al. Current Progresses of Exosomes as Cancer Diagnostic and Prognostic Biomarkers , 2019, International journal of biological sciences.
[13] A. Godwin,et al. Ultrasensitive quantification of tumor mRNAs in extracellular vesicles with an integrated microfluidic digital analysis chip. , 2018, Lab on a chip.
[14] X. Xie,et al. Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases. , 2018, Cancer research.
[15] B. Liu,et al. Significance of circulating tumor cells in osteosarcoma patients treated by neoadjuvant chemotherapy and surgery , 2018, Cancer management and research.
[16] Li-li Li,et al. Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV , 2018, International journal of oncology.
[17] Shuai Zhang,et al. MicroRNA-34b promotes proliferation, migration and invasion of Ewing's sarcoma cells by downregulating Notch1 , 2018, Molecular medicine reports.
[18] M. Heymann,et al. Isolation of circulating tumor cells in a preclinical model of osteosarcoma: Effect of chemotherapy , 2018, Journal of bone oncology.
[19] Peng Su,et al. Diagnostic and prognostic values of blood microRNA-Let7A for osteosarcoma , 2018, Journal of bone oncology.
[20] Qiaojun He,et al. KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells , 2018, Acta Pharmacologica Sinica.
[21] B. Casini,et al. Precision diagnostics of Ewing’s sarcoma by liquid biopsy: circulating EWS-FLI1 fusion transcripts , 2018, Therapeutic advances in medical oncology.
[22] C. Garbutt,et al. Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma , 2018, Cell Death & Disease.
[23] P. Paterlini-Bréchot,et al. EGFR expression in circulating tumor cells from high-grade metastatic soft tissue sarcomas , 2018, Cancer biology & therapy.
[24] M. López-Lázaro,et al. The stem cell division theory of cancer. , 2018, Critical reviews in oncology/hematology.
[25] R. Neumann,et al. Circulating tumour-derived DNA in metastatic soft tissue sarcoma , 2018, Oncotarget.
[26] S. Ferrari,et al. Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients , 2018, Cancer management and research.
[27] S. Avnet,et al. Prominent role of RAB39A-RXRB axis in cancer development and stemness , 2018, Oncotarget.
[28] Shulin Li,et al. Cell-surface vimentin–positive macrophage-like circulating tumor cells as a novel biomarker of metastatic gastrointestinal stromal tumors , 2017, Oncoimmunology.
[29] M. Heymann,et al. Biology of Bone Sarcomas and New Therapeutic Developments , 2017, Calcified Tissue International.
[30] S. Avnet,et al. Mesenchymal stroma: Role in osteosarcoma progression. , 2017, Cancer letters.
[31] Shulin Li,et al. Detection of circulating tumor cells from cryopreserved human sarcoma peripheral blood mononuclear cells. , 2017, Cancer letters.
[32] Hua Zou,et al. miR-491 Inhibits Osteosarcoma Lung Metastasis and Chemoresistance by Targeting αB-crystallin. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[33] V. Plagnol,et al. Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection , 2017, Cancer medicine.
[34] H. Bannasch,et al. Levels of activated platelet-derived microvesicles in patients with soft tissue sarcoma correlate with an increased risk of venous thromboembolism , 2017, BMC Cancer.
[35] Y. Lu,et al. [Detection and clinical significance of circulating tumor cells in osteosarcoma using immunofluorescence combined with in situ hybridization]. , 2017, Zhonghua zhong liu za zhi [Chinese journal of oncology].
[36] Peng Zhang,et al. MiR-129-5p Inhibits Proliferation and Invasion of Chondrosarcoma Cells by Regulating SOX4/Wnt/β-Catenin Signaling Pathway , 2017, Cellular Physiology and Biochemistry.
[37] A. Viale,et al. Plasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomas. , 2017, JCO precision oncology.
[38] A. Satelli,et al. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression , 2017, Oncotarget.
[39] Chih-Hsin Tang,et al. WISP-3 inhibition of miR-452 promotes VEGF-A expression in chondrosarcoma cells and induces endothelial progenitor cells angiogenesis , 2017, Oncotarget.
[40] C. Garbutt,et al. Potentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets , 2017, International journal of molecular sciences.
[41] T. Ochiya,et al. Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma , 2017, Oncotarget.
[42] Chen Huang,et al. A liquid biopsy-based method for the detection and quantification of circulating tumor cells in surgical osteosarcoma patients , 2017, International journal of oncology.
[43] A. Bardelli,et al. Integrating liquid biopsies into the management of cancer , 2017, Nature Reviews Clinical Oncology.
[44] Nathan C. Sheffield,et al. Epigenetik erklärt Vielfalt von Krebs bei Kindern , 2017, TumorDiagnostik & Therapie.
[45] R. Shen,et al. The clinical significance of the Ezrin gene and circulating tumor cells in osteosarcoma , 2017, OncoTargets and Therapy.
[46] D. Heymann,et al. Cancer stem cells in osteosarcoma. , 2017, Cancer letters.
[47] W. Guo,et al. Knockdown of long non-coding RNA HOTAIR increases miR-454-3p by targeting Stat3 and Atg12 to inhibit chondrosarcoma growth , 2017, Cell Death & Disease.
[48] Juanjuan Wen,et al. Analysis of circulating long non-coding RNA UCA1 as potential biomarkers for diagnosis and prognosis of osteosarcoma. , 2017, European review for medical and pharmacological sciences.
[49] U. Dirksen,et al. Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells , 2017, Oncogene.
[50] Nathan C. Sheffield,et al. DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma , 2017, Nature Medicine.
[51] T. Lagerweij,et al. Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression , 2017, Clinical Cancer Research.
[52] G. Rosen,et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas , 2016, Clinical Sarcoma Research.
[53] L. Pagliaro,et al. Clinically Meaningful Use of Blood Tumor Markers in Oncology , 2016, BioMed research international.
[54] H. Mankin,et al. miR‐15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo , 2016, Molecular oncology.
[55] C. Camps,et al. Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? , 2016, Translational lung cancer research.
[56] Xijing He,et al. Combined over-expression of the hypoxia-inducible factor 2α gene and its long non-coding RNA predicts unfavorable prognosis of patients with osteosarcoma. , 2016, Pathology, research and practice.
[57] M. Heymann,et al. Drugs in early clinical development for the treatment of osteosarcoma , 2016, Expert opinion on investigational drugs.
[58] D. Lian,et al. Long non-coding RNA MALAT1 is an independent prognostic factor of osteosarcoma. , 2016, European review for medical and pharmacological sciences.
[59] Jingang Tao,et al. Upregulation of lncRNA HNF1A-AS1 promotes cell proliferation and metastasis in osteosarcoma through activation of the Wnt/β-catenin signaling pathway. , 2016, American journal of translational research.
[60] Fenyong Chen,et al. Long noncoding RNA BCAR4 promotes osteosarcoma progression through activating GLI2-dependent gene transcription , 2016, Tumor Biology.
[61] Z. Duan,et al. The roles and implications of exosomes in sarcoma , 2016, Cancer and Metastasis Reviews.
[62] U. Dirksen,et al. Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma , 2016, Clinical Cancer Research.
[63] L. Alexandrov,et al. Base changes in tumour DNA have the power to reveal the causes and evolution of cancer , 2016, Oncogene.
[64] C. Scapulatempo-Neto,et al. High Expression of HULC Is Associated with Poor Prognosis in Osteosarcoma Patients , 2016, PloS one.
[65] G. Stein,et al. Proteomic Analysis of Exosomes and Exosome‐Free Conditioned Media From Human Osteosarcoma Cell Lines Reveals Secretion of Proteins Related to Tumor Progression , 2016, Journal of cellular biochemistry.
[66] G. Vunjak‐Novakovic,et al. Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model , 2016, Theranostics.
[67] O. P. Camargo,et al. SERUM VALUES OF ALKALINE PHOSPHATASE AND LACTATE DEHYDROGENASE IN OSTEOSARCOMA , 2016, Acta ortopedica brasileira.
[68] N. Zhang,et al. Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing , 2016, PloS one.
[69] P. Brousset,et al. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[70] D. Heymann,et al. Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation. , 2016, Clinical chemistry.
[71] Meng Li,et al. Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma , 2016, Tumor Biology.
[72] Donghui Zheng,et al. Genetic variants of lncRNA HOTAIR contribute to the risk of osteosarcoma , 2016, Oncotarget.
[73] Leon W M M Terstappen,et al. Challenges in circulating tumor cell detection by the CellSearch system , 2016, Molecular oncology.
[74] W. Ren,et al. Circulating miR-125b as a biomarker of Ewing's sarcoma in Chinese children. , 2015, Genetics and molecular research : GMR.
[75] Roman Kaliszan,et al. Metabolomics for laboratory diagnostics. , 2015, Journal of pharmaceutical and biomedical analysis.
[76] F. Wang,et al. Long non-coding RNA HOTTIP is up-regulated and associated with poor prognosis in patients with osteosarcoma. , 2015, International journal of clinical and experimental pathology.
[77] B. Sartorius,et al. Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma , 2015, Journal of bone oncology.
[78] K. S. Hall,et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[79] P. Mukhopadhyay,et al. Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis , 2015, PloS one.
[80] Robin L. Jones,et al. Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma , 2015, Rare tumors.
[81] E. Rohren,et al. Alpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier Penetration. , 2015, JAMA oncology.
[82] D. Placantonakis,et al. Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells , 2015, Nature Communications.
[83] Jie Tang,et al. Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma. , 2015, The Journal of surgical research.
[84] L. Donehower,et al. Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma , 2015, Cancer medicine.
[85] Liwen Wu,et al. Identification of a Plasma Four-microRNA Panel as Potential Noninvasive Biomarker for Osteosarcoma , 2015, PloS one.
[86] Li-bin Yang,et al. Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma. , 2015, International journal of clinical and experimental pathology.
[87] T. Triche,et al. Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression , 2015, Clinical Cancer Research.
[88] Chun-Hao Tsai,et al. CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells. , 2015, Cancer letters.
[89] Zheng Li,et al. MicroRNA expression and its clinical implications in Ewing's sarcoma , 2015, Cell proliferation.
[90] L. Ellis,et al. Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression , 2014, Clinical Cancer Research.
[91] Marcus R. Breese,et al. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. , 2014, The Journal of clinical investigation.
[92] I. Amelio,et al. TAp73 promotes anabolism , 2014, Oncotarget.
[93] Piero Picci,et al. Quantification of the Heterogeneity of Prognostic Cellular Biomarkers in Ewing Sarcoma Using Automated Image and Random Survival Forest Analysis , 2014, PloS one.
[94] P. Paterlini-Bréchot,et al. Isolation, detection, and immunomorphological characterization of circulating tumor cells (CTCs) from patients with different types of sarcoma using isolation by size of tumor cells: a window on sarcoma-cell invasion , 2014, OncoTargets and therapy.
[95] L. Dai,et al. Serum miR-9 as a prognostic biomarker in patients with osteosarcoma , 2014, The Journal of international medical research.
[96] David M. Thomas,et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing , 2014, BMC Medical Genomics.
[97] Carl R Walkley,et al. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? , 2014, Bone.
[98] J. Huard,et al. ALDH Activity Correlates with Metastatic Potential in Primary Sarcomas of Bone. , 2014, Journal of cancer therapy.
[99] A. Satelli,et al. Universal marker and detection tool for human sarcoma circulating tumor cells. , 2014, Cancer research.
[100] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[101] M. Heymann,et al. Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma? , 2013, Expert opinion on emerging drugs.
[102] G. Raposo,et al. First identification of Ewing's sarcoma‐derived extracellular vesicles and exploration of their biological and potential diagnostic implications , 2013, Biology of the cell.
[103] L. Ouyang,et al. A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma , 2013, Medical Oncology.
[104] H. Jung,et al. Continuous labeling of circulating tumor cells with microbeads using a vortex micromixer for highly selective isolation. , 2013, Biosensors & bioelectronics.
[105] Wei Liu,et al. CD133 expression in osteosarcoma and derivation of CD133⁺ cells. , 2013, Molecular medicine reports.
[106] K. Nagashima,et al. Identification of CBX3 and ABCA5 as Putative Biomarkers for Tumor Stem Cells in Osteosarcoma , 2012, PloS one.
[107] X. Liang,et al. Expression of Aurora Kinase A and B in chondrosarcoma and its relationship with the prognosis , 2012, Diagnostic Pathology.
[108] Man Yu,et al. Cell-free circulating mitochondrial DNA in the serum: a potential non-invasive biomarker for Ewing's sarcoma. , 2012, Archives of medical research.
[109] A. Testori,et al. Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread? , 2012, Clinical & Experimental Metastasis.
[110] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[111] B. Qian,et al. Increased expression of insulin‐like growth factor‐1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma , 2012, Journal of surgical oncology.
[112] Liangqun Rong,et al. Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma , 2012, Molecular medicine reports.
[113] N. Onishi,et al. Fibroblast Growth Factor-2 Is an Important Factor that Maintains Cellular Immaturity and Contributes to Aggressiveness of Osteosarcoma , 2012, Molecular Cancer Research.
[114] S. Rauser,et al. CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients , 2011, Oncotarget.
[115] S. Kharb,et al. Serum Fluoride and Sialic Acid Levels in Osteosarcoma , 2011, Biological Trace Element Research.
[116] M. Etchebehere,et al. Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors – clinical and histological correlation , 2011, Clinics.
[117] B. Song,et al. Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is associated with increased risk of osteosarcoma. , 2011, Genetic testing and molecular biomarkers.
[118] N. Akyürek,et al. The Evaluation of CD99 Immunoreactivity and EWS/FLI1 Translocation by Fluorescence in situ Hybridization in Central PNETs and Ewing’s Sarcoma Family of Tumors , 2011, Pathology & Oncology Research.
[119] I. McGonnell,et al. Expression of Snail2 in long bone osteosarcomas correlates with tumour malignancy , 2011, Tumor Biology.
[120] Xin Shi,et al. Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma , 2010, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[121] D. LeBrun,et al. FLI-1 Distinguishes Ewing Sarcoma From Small Cell Osteosarcoma and Mesenchymal Chondrosarcoma , 2010, Applied immunohistochemistry & molecular morphology : AIMM.
[122] Wei Sun,et al. Serum and urinary metabonomic study of human osteosarcoma. , 2010, Journal of proteome research.
[123] Toshio Mori,et al. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. , 2010, Oncology reports.
[124] A. Petrilli,et al. Glutathione S-transferase polymorphisms in osteosarcoma patients , 2010, Pharmacogenetics and genomics.
[125] A. Lopes,et al. Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis. , 2010, The Journal of bone and joint surgery. American volume.
[126] Aaron R Cooper,et al. Intercohort Gene Expression Co-Analysis Reveals Chemokine Receptors as Prognostic Indicators in Ewing's Sarcoma , 2010, Clinical Cancer Research.
[127] N. Agarwal,et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. , 2010, Cancer research.
[128] D. Herrero-Martín,et al. The molecular pathogenesis of Ewing sarcoma , 2010, Cancer biology & therapy.
[129] Yong Zhang,et al. Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study , 2010, BMC Cancer.
[130] Weichun Guo,et al. Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma , 2010, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[131] Naomi J Balamuth,et al. Ewing's sarcoma. , 2010, The Lancet. Oncology.
[132] G. Machak,et al. Endostatin, Placental Growth Factor, and Fibroblast Growth Factors-1 and -2 in the Sera of Patients with Primary Osteosarcomas , 2009, Bulletin of Experimental Biology and Medicine.
[133] P. Hogendoorn,et al. Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes , 2009, Modern Pathology.
[134] A. Patiño-García,et al. Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets. , 2009, Journal of proteome research.
[135] Hye-Rim Park,et al. Prognostic Implication of Immunohistochemical Runx2 Expression in Osteosarcoma , 2009, Tumori.
[136] Y. Takakura,et al. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. , 2009, International journal of oncology.
[137] S. Knuutila,et al. Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors , 2009, Clinical Cancer Research.
[138] E. Barillot,et al. The Oncogenic EWS-FLI1 Protein Binds In Vivo GGAA Microsatellite Sequences with Potential Transcriptional Activation Function , 2009, PloS one.
[139] H Kovar,et al. O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma , 2009, Oncogene.
[140] S. Nelson,et al. Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing's family tumors , 2008, Laboratory Investigation.
[141] A. Montag,et al. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects , 2008, Laboratory Investigation.
[142] W. Dong,et al. Expression of c-kit Protein and Mutational Status of the c-kit Gene in Osteosarcoma and Their Clinicopathological Significance , 2008, The Journal of international medical research.
[143] P. Picci,et al. Prognostic Value of CCN3 in Osteosarcoma , 2008, Clinical Cancer Research.
[144] A. Cleton-Jansen,et al. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas , 2005, The Journal of pathology.
[145] A. Chan,et al. Quantitative analysis of circulating tumor cells in peripheral blood of osteosarcoma patients using osteoblast-specific messenger RNA markers: a pilot study. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[146] M. Heymann,et al. The Heterogeneity of Osteosarcoma: The Role Played by Cancer Stem Cells. , 2019, Advances in experimental medicine and biology.
[147] D. Heymann,et al. Circulating Tumor Cells: The Importance of Single Cell Analysis. , 2018, Advances in experimental medicine and biology.
[148] A. Rosenberg. Bone Sarcoma Pathology: Diagnostic Approach for Optimal Therapy. , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[149] Zhanghua Li,et al. Effects of altered CXCL12/CXCR4 axis on BMP2/Smad/Runx2/Osterix axis and osteogenic gene expressions during osteogenic differentiation of MSCs. , 2017, American journal of translational research.
[150] Jianjun Lin,et al. Long noncoding RNA ZEB1-AS1 acts as an oncogene in osteosarcoma by epigenetically activating ZEB1. , 2016, American journal of translational research.
[151] O. P. de Camargo,et al. SERUM VALUES OF ALKALINE PHOSPHATASE AND LACTATE DEHYDROGENASE IN EWING'S SARCOMA , 2016, Acta ortopedica brasileira.
[152] M. Heymann,et al. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers , 2015, Journal of bone oncology.
[153] Zhiming Liu,et al. Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions , 2015, Clinical chemistry and laboratory medicine.
[154] J. Peppercorn. Toward improved understanding of the ethical and clinical issues surrounding mandatory research biopsies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[155] Song Jin,et al. Increased expression of serum gelsolin in patients with osteosarcoma. , 2012, Chinese Medical Journal.
[156] A. D. Dei Tos,et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[157] P. Meltzer,et al. Molecular and Cellular Pathobiology Cancer Research Hypoxia Modulates EWS-FLI 1 Transcriptional Signature and Enhances the Malignant Properties of Ewing ' s Sarcoma Cells In vitro , 2010 .
[158] O. Delattre,et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[159] R. Grimer,et al. Risk factors for survival and local control in chondrosarcoma of bone. , 2002, The Journal of bone and joint surgery. British volume.